CEP
DRNA

Chicago Equity Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Chicago Equity Partners’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$274K Buy
+14,910
New +$290K 0.03% 551

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Chicago Equity Partners's DRNA Position: Q1 2020 in Review

Chicago Equity Partners opened a new position in Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2020: 14,910 shares worth $274K. The stake represents 0.03% of the portfolio and ranks #551 among its holdings.

144 funds tracked by Wall St. Rank hold DRNA as of Q1 2020.

  • Chicago Equity Partners held 14,910 shares of Dicerna Pharmaceuticals, Inc. worth $274K as of Q1 2020.
  • Dicerna Pharmaceuticals, Inc. was a new Chicago Equity Partners position in Q1 2020.
  • Dicerna Pharmaceuticals, Inc. made up 0.03% of Chicago Equity Partners's portfolio in Q1 2020, its #551 holding.
  • 144 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.